Showing results (411-420 of 449) with videos related to

Sort By:
Pageof 45
Journal of Hematology & Oncology|January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert PanelJ Caers, B Paiva, E Zamagni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcomeM Michallet, K Bilger, F Garban, et al.
Bone Marrow Transplantation|March 29, 2011
Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantationZ Peric, X Cahu, P Chevallier, et al.
Bone Marrow Transplantation|June 12, 2002
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapyS Vigouroux, N Milpied, J M Andrieu, et al.
Leukemia|February 26, 2011
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantationZ Peric, X Cahu, P Chevallier, et al.
Leukemia|August 10, 2012
Minor clone provides a reservoir for relapse in multiple myelomaF Magrangeas, H Avet-Loiseau, W Gouraud, et al.
Blood Cancer Journal|April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatmentM A Dimopoulos, A K Stewart, T Masszi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2012
Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experienceS Le Gouill, N Kröger, N Dhedin, et al.
Leukemia|April 16, 2014
Gene expression profile alone is inadequate in predicting complete response in multiple myelomaS B Amin, W-K Yip, S Minvielle, et al.
Annals of Hematology|April 5, 2017
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomasB Tessoulin, P Thomare, E Delande, et al.
Pageof 45